Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.

COVID–19 SARS–CoV–2 doubling time genomic survey omicron prevalence

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
11 2022
Historique:
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 15 11 2022
Statut: ppublish

Résumé

BackgroundThe SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021.AimTo comprehensively describe Omicron spread in Italy in the 2 subsequent months and its impact on the overall SARS-CoV-2 circulation at population level.MethodsWe analyse data from four genomic surveys conducted across the country between December 2021 and January 2022. Combining genomic sequencing results with epidemiological records collated by the National Integrated Surveillance System, the Omicron reproductive number and exponential growth rate are estimated, as well as SARS-CoV-2 transmissibility.ResultsOmicron became dominant in Italy less than 1 month after its first detection, representing on 3 January 76.9-80.2% of notified SARS-CoV-2 infections, with a doubling time of 2.7-3.3 days. As of 17 January 2022, Delta variant represented < 6% of cases. During the Omicron expansion in December 2021, the estimated mean net reproduction numbers respectively rose from 1.15 to a maximum of 1.83 for symptomatic cases and from 1.14 to 1.36 for hospitalised cases, while remaining relatively stable, between 0.93 and 1.21, for cases needing intensive care. Despite a reduction in relative proportion, Delta infections increased in absolute terms throughout December contributing to an increase in hospitalisations. A significant reproduction numbers' decline was found after mid-January, with average estimates dropping below 1 between 10 and 16 January 2022.ConclusionEstimates suggest a marked growth advantage of Omicron compared with Delta variant, but lower disease severity at population level possibly due to residual immunity against severe outcomes acquired from vaccination and prior infection.

Identifiants

pubmed: 36367013
doi: 10.2807/1560-7917.ES.2022.27.45.2200125
pmc: PMC9650705
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Martina Del Manso (M)
Matteo Spuri (M)
Chiara Sacco (C)
Massimo Fabiani (M)
Marco Bressi (M)
Alberto Mateo-Urdiales (A)
Maria Fenicia Vescio (M)
Alessandra Lo Presti (A)
Stefano Morabito (S)
Gabriele Vaccari (G)
Ilaria Di Bartolo (I)
Arnold Knijn (A)
Luca De Sabato (L)
Liborio Stuppia (L)
Giovanni Savini (G)
Antonio Picerno (A)
Teresa Lopizzo (T)
Domenico Dell'Edera (D)
Pasquale Minchella (P)
Francesca Greco (F)
Giuseppe Viglietto (G)
Maria Teresa Fiorillo (MT)
Luigi Atripaldi (L)
Antonio Limone (A)
Davide Cacchiarelli (D)
Pierlanfranco D'Agaro (P)
Danilo Licastro (D)
Stefano Pongolini (S)
Tiziana Lazzarotto (T)
Giada Rossini (G)
Vittorio Sambri (V)
Giorgio Dirani (G)
Silvia Zannoli (S)
Paola Affanni (P)
Maria Eugenia Colucci (ME)
Maria Rosaria Capobianchi (MR)
Florigio Lista (F)
Anna Anselmo (A)
Patricia Alba (P)
Alice Massacci (A)
Carlo Federico Perno (CF)
Maurizio Sanguinetti (M)
Bianca Bruzzone (B)
Giancarlo Icardi (G)
Flavia Lillo (F)
Andrea Orsi (A)
Elena Pariani (E)
Fausto Baldanti (F)
Maria Rita Gismondo (MR)
Valeria Micheli (V)
Fabrizio Maggi (F)
Arnaldo Caruso (A)
Ferruccio Ceriotti (F)
Maria Beatrice Boniotti (MB)
Ilaria Barbieri (I)
Alice Nava (A)
Erminio Torresani (E)
Fabiana Cro (F)
Enzo Boeri (E)
Marina Noris (M)
Giulia Bassanini (G)
Claudio Farina (C)
Marco Arosio (M)
Sergio Malandrin (S)
Annalisa Cavallero (A)
Patrizia Bagnarelli (P)
Stefano Menzo (S)
Silvio Garofalo (S)
Massimiliano Scutellà (M)
Elisabetta Pagani (E)
Lucia Collini (L)
Valeria Ghisetti (V)
Silvia Brossa (S)
Giuseppe Ru (G)
Elena Bozzetta (E)
Maria Chironna (M)
Antonio Parisi (A)
Salvatore Rubino (S)
Sergio Uzzau (S)
Flavia Angioj (F)
Gabriele Ibba (G)
Caterina Serra (C)
Giovanna Piras (G)
Giuseppe Mameli (G)
Ferdinando Coghe (F)
Francesco Vitale (F)
Fabio Tramuto (F)
Guido Scalia (G)
Concetta Ilenia Palermo (CI)
Giuseppe Mancuso (G)
Teresa Pollicino (T)
Francesca Di Gaudio (F)
Stefano Vullo (S)
Stefano Reale (S)
Maria Grazia Cusi (MG)
Gian Maria Rossolini (GM)
Mauro Pistello (M)
Antonella Mencacci (A)
Barbara Camilloni (B)
Silvano Severini (S)
Massimo Di Benedetto (M)
Calogero Terregino (C)
Alice Fusaro (A)
Mosè Favarato (M)
Laura Squarzon (L)
Isabella Monne (I)
Valeria Biscaro (V)

Références

Trop Med Int Health. 2022 Jun;27(6):564-573
pubmed: 35411997
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Euro Surveill. 2022 May;27(18):
pubmed: 35514304
Nat Commun. 2021 Mar 9;12(1):1533
pubmed: 33750783
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
BMJ Open. 2020 Nov 23;10(11):e040263
pubmed: 33234640
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720639
Lancet Infect Dis. 2022 Jul;22(7):931-933
pubmed: 35623379
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Viruses. 2022 Jan 30;14(2):
pubmed: 35215887
Epidemics. 2021 Dec;37:100528
pubmed: 34814093
Lancet Reg Health Eur. 2022 Aug;19:100446
pubmed: 35791373

Auteurs

Paola Stefanelli (P)

Istituto Superiore di Sanità, Rome, Italy.

Filippo Trentini (F)

Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Daniele Petrone (D)

Istituto Superiore di Sanità, Rome, Italy.

Alessia Mammone (A)

Health Prevention Directorate, Ministry of Health, Rome, Italy.

Luigina Ambrosio (L)

Istituto Superiore di Sanità, Rome, Italy.

Mattia Manica (M)

Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Giorgio Guzzetta (G)

Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Valeria d'Andrea (V)

Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Valentina Marziano (V)

Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Agnese Zardini (A)

Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Carla Molina Grane' (C)

University of Trento, Trento, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Marco Ajelli (M)

Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, United States.

Angela Di Martino (A)

Istituto Superiore di Sanità, Rome, Italy.

Flavia Riccardo (F)

Istituto Superiore di Sanità, Rome, Italy.

Antonino Bella (A)

Istituto Superiore di Sanità, Rome, Italy.

Monica Sane Schepisi (M)

Health Prevention Directorate, Ministry of Health, Rome, Italy.

Francesco Maraglino (F)

Health Prevention Directorate, Ministry of Health, Rome, Italy.

Piero Poletti (P)

Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.

Anna Teresa Palamara (AT)

Istituto Superiore di Sanità, Rome, Italy.

Silvio Brusaferro (S)

Istituto Superiore di Sanità, Rome, Italy.

Giovanni Rezza (G)

Health Prevention Directorate, Ministry of Health, Rome, Italy.

Patrizio Pezzotti (P)

Istituto Superiore di Sanità, Rome, Italy.

Stefano Merler (S)

Epilab-JRU, FEM-FBK Joint Research Unit, Trento, Italy.
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy.
The members of the Genomic SARS-CoV-2 National Surveillance Working Group are listed under Collaborators.
The members of the Italian Integrated Surveillance of COVID-19 Study Group are listed under Collaborators.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH